Philippines' health secretary plans to ask Sanofi for a Dengvaxia refund and to sue the drugmaker amid worries about the dengue shot's safety.

Preliminary results from a trio of phase 1 studies showed promise for the Zika vaccine Sanofi had previously left behind.

Here's some other vaccine news of note for the week.

On the heels of a safety warning, the Philippines' FDA ordered Sanofi to pull its Dengvaxia shot from the market.

With financial support from BARDA, Takeda's purified, inactivated, alum-adjuvanted Zika vaccine has entered human testing.

Before heading offshore for a dubious herpes vaccine trial, a Southern Illinois University did such experiments on people in the U.S.

Immunovaccine and Leidos are working together to determine the most promising malaria vaccine formulations.

Now that Prostvac has failed as a stand-alone therapy, Bavarian Nordic's MVA-BN RSV vaccine is now extra-important.